183 related articles for article (PubMed ID: 33563150)
21. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of inhibition of viral RNA replication by nucleotide analogs.
Johnson KA; Dangerfield T
Enzymes; 2021; 49():39-62. PubMed ID: 34696838
[TBL] [Abstract][Full Text] [Related]
23. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
Wakchaure PD; Ghosh S; Ganguly B
J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
[TBL] [Abstract][Full Text] [Related]
24. Endogenous G-quadruplex-forming RNAs inhibit the activity of SARS-CoV-2 RNA polymerase.
Endoh T; Takahashi S; Sugimoto N
Chem Commun (Camb); 2023 Jan; 59(7):872-875. PubMed ID: 36594508
[TBL] [Abstract][Full Text] [Related]
25. Recent Advances Towards Drug Design Targeting the Protease of 2019 Novel Coronavirus (2019-nCoV).
Bano S; Hameed A; Al-Rashida M; Iftikhar S; Iqbal J
Curr Med Chem; 2021; 28(22):4484-4498. PubMed ID: 33109027
[TBL] [Abstract][Full Text] [Related]
26. Structural Insights into the Binding Modes of Viral RNA-Dependent RNA Polymerases Using a Function-Site Interaction Fingerprint Method for RNA Virus Drug Discovery.
Zhao Z; Bourne PE
J Proteome Res; 2020 Nov; 19(11):4698-4705. PubMed ID: 32946692
[TBL] [Abstract][Full Text] [Related]
27. Structure of the RNA-dependent RNA polymerase from COVID-19 virus.
Gao Y; Yan L; Huang Y; Liu F; Zhao Y; Cao L; Wang T; Sun Q; Ming Z; Zhang L; Ge J; Zheng L; Zhang Y; Wang H; Zhu Y; Zhu C; Hu T; Hua T; Zhang B; Yang X; Li J; Yang H; Liu Z; Xu W; Guddat LW; Wang Q; Lou Z; Rao Z
Science; 2020 May; 368(6492):779-782. PubMed ID: 32277040
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Viral RNA-Dependent RNA Polymerases by Nucleoside Inhibitors: An Illustration of the Unity and Diversity of Mechanisms.
Barik S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293509
[TBL] [Abstract][Full Text] [Related]
29. New anti-viral drugs for the treatment of COVID-19 instead of favipiravir.
Aktaş A; Tüzün B; Aslan R; Sayin K; Ataseven H
J Biomol Struct Dyn; 2021 Nov; 39(18):7263-7273. PubMed ID: 32783586
[TBL] [Abstract][Full Text] [Related]
30. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
31. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase.
Wang Q; Wu J; Wang H; Gao Y; Liu Q; Mu A; Ji W; Yan L; Zhu Y; Zhu C; Fang X; Yang X; Huang Y; Gao H; Liu F; Ge J; Sun Q; Yang X; Xu W; Liu Z; Yang H; Lou Z; Jiang B; Guddat LW; Gong P; Rao Z
Cell; 2020 Jul; 182(2):417-428.e13. PubMed ID: 32526208
[TBL] [Abstract][Full Text] [Related]
32. Non-nucleoside Inhibitors of Zika Virus RNA-Dependent RNA Polymerase.
Gharbi-Ayachi A; Santhanakrishnan S; Wong YH; Chan KWK; Tan ST; Bates RW; Vasudevan SG; El Sahili A; Lescar J
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796069
[TBL] [Abstract][Full Text] [Related]
33. The Unusual Architecture of RNA-Dependent RNA Polymerase (RdRp)'s Catalytic Chamber Provides a Potential Strategy for Combination Therapy against COVID-19.
Metwally K; Abo-Dya NE; Alahmdi MI; Albalawi MZ; Yahya G; Aljoundi A; Salifu EY; Elamin G; Ibrahim MAA; Sayed Y; Fanucchi S; Soliman MES
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985777
[TBL] [Abstract][Full Text] [Related]
34. RNA: The most attractive target in recent viral diseases.
Rabie AM
Chem Biol Drug Des; 2024 Jan; 103(1):e14404. PubMed ID: 38092663
[TBL] [Abstract][Full Text] [Related]
35. Modeling the Enzymatic Mechanism of the SARS-CoV-2 RNA-Dependent RNA Polymerase by DFT/MM-MD: An Unusual Active Site Leading to High Replication Rates.
Bignon E; Monari A
J Chem Inf Model; 2022 Sep; 62(17):4261-4269. PubMed ID: 35982544
[TBL] [Abstract][Full Text] [Related]
36. [The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis].
Gaisenok OV
Vopr Virusol; 2020 Jul; 65(3):167-175. PubMed ID: 33533219
[TBL] [Abstract][Full Text] [Related]
37. Exploring new antiviral targets for influenza and COVID-19: Mapping promising hot spots in viral RNA polymerases.
Figueiredo-Nunes I; Trigueiro-Louro J; Rebelo-de-Andrade H
Virology; 2023 Jan; 578():45-60. PubMed ID: 36463618
[TBL] [Abstract][Full Text] [Related]
38. A Helquat-like Compound as a Potent Inhibitor of Flaviviral and Coronaviral Polymerases.
Konkolova E; Krejčová K; Eyer L; Hodek J; Zgarbová M; Fořtová A; Jirasek M; Teply F; Reyes-Gutierrez PE; Růžek D; Weber J; Boura E
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335258
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs.
Maheden K; Todd B; Gordon CJ; Tchesnokov EP; Götte M
Enzymes; 2021; 49():315-354. PubMed ID: 34696837
[TBL] [Abstract][Full Text] [Related]
40. RNA Interference Approach Is a Good Strategy against SARS-CoV-2.
Lee YR; Tsai HP; Yeh CS; Fang CY; Chan MWY; Wu TY; Shen CH
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
